On April 15, Dongfang Wealth Securities released a research report stating that Kangyuan Pharmaceutical (600557.SH) was given an increase in its holdings rating. The main reasons for the rating include: 1) performance continues to grow under a high base; 2) the company's products are rich in basic medicine and medical insurance; 3) continuous investment and remarkable results in R&D; 4) reasonable cost control without controlling talent investment. (Mainichi Keizai Shimbun)
东方财富证券4月15日发布研报称，给予康缘药业（600557.SH）增持评级。评级理由主要包括：1）业绩在高基数情形下保持增长；2）公司产品丰富基药医保品种多；3）持续加大投入研发成果显著；4）合理控费不控人才投入。（每日经济新闻）
On April 15, Dongfang Wealth Securities released a research report stating that Kangyuan Pharmaceutical (600557.SH) was given an increase in its holdings rating. The main reasons for the rating include: 1) performance continues to grow under a high base;
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.